SCHEMBL1964559

SCHEMBL1964559

CC(C)(C)OC(=O)N(Cc1ccccc1C(F)(F)F)n1cccc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.44
POLB P06746 1/20 0.44
SLC6A2 P23975 8/20 0.42
SLC6A4 P31645 8/20 0.42
SLC6A3 Q01959 3/20 0.42
POLQ O75417 1/20 0.41
MAOB P27338 2/20 0.40
MAOA P21397 1/20 0.40
ACHE P22303 1/20 0.39
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
GAA P10253 1/20 0.38
ATM Q13315 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
IDO1 P14902 1/20 0.37
BMP1 P13497 1/20 0.37
RORC P51449 1/20 0.37
ACKR3 P25106 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1964210 0.84 RIPK1 (0.46) KDM4EALDH1A1GAAATM
SCHEMBL1966140 0.82 NPC1 (0.39) LMNAMAOBMAOAACHEALDH1A1
SCHEMBL1964950 0.80 AKT1 (0.46) SLC6A4
SCHEMBL1966228 0.80 MEN1 (0.41) MAOBKDM4EALDH1A1
SCHEMBL1964518 0.78 RIPK1 (0.46) SLC6A4MAOBRORC
SCHEMBL1966223 0.77 ALDH1A1 (0.42) MAOBKDM4EALDH1A1GAA
SCHEMBL1966131 0.76 KDM1A (0.42) TDP1
SCHEMBL1965415 0.76 GPR119 (0.36) KDM4EALDH1A1GAARORC
SCHEMBL1965400 0.74 GAA (0.40) LMNAKDM4EALDH1A1GAANPSR1
SCHEMBL1965084 0.73 CTSB (0.40) SLC6A2SLC6A4SLC6A3ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334682-B1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN INC (US) 2017-10-04 EP disclosed
US-8217043-B2 Compounds and methods for their use FIBROGEN, INC. (US) 2012-07-10 US disclosed
EP-2334682-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS Fibrogen, Inc. (US) 2011-06-22 EP disclosed
WO-2010022240-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN, INC. (US) 2010-02-25 WO disclosed
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE FIBROGEN, INC. 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE HIF1AN, HIF1A, EGLN3 LMNA 3079/4885POLB 857/4885SLC6A2 3607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.